Q2 2019 Highlights
- Total revenue, including royalty and other revenue, was $229.7
million;
- Product revenue increased 13.6% to $229.5 million, or 14.8% on
a constant currency basis;
- GAAP net income per diluted share was $0.79; and
- Non-GAAP net income per diluted share increased 24.6% to
$0.76.
Masimo (NASDAQ: MASI) today announced its financial results for
the second quarter ended June 29, 2019.
Second Quarter 2019 Results:
Total revenue, including royalty and other revenue, was $229.7
million. Product revenue increased 13.6% to $229.5 million, or
14.8% on a constant currency basis. Shipments of noninvasive
technology boards and monitors increased approximately 2.9% to
60,400 in the second quarter of 2019, compared to 58,700 in the
second quarter of 2018.
GAAP operating margin was 22.6%. Non-GAAP operating margin
increased 200 basis points to 23.1%, compared to 21.1% in the prior
year period.
For the second quarter of 2019, GAAP net income was $44.9
million or $0.79 per diluted share. Non-GAAP net income was $43.1
million or $0.76 per diluted share, a 24.6% increase compared to
$0.61 per diluted share in the prior year period.
The Company repurchased approximately 208,000 shares of Masimo
common stock for a total cost of approximately $27.9 million during
the second quarter of 2019. Total cash and short-term investments
was $588.8 million as of June 29, 2019.
As a result of the strong performance in the second quarter,
Masimo is again raising its guidance for fiscal year 2019. The
Company now expects product revenue of $925.0 million, which
reflects reported growth of 11.5% and constant currency growth of
12.2%. Masimo is also raising its GAAP EPS guidance to $3.30 and
its non-GAAP EPS guidance to $3.15.
Joe Kiani, Chairman and Chief Executive Officer of Masimo, said,
“The first half of 2019 has been strong with second quarter
constant currency product revenue growth of 14.8% and non-GAAP
earnings per share growth of 25%. We are happy to report second
quarter results that once again exceeded expectations. Our
breakthrough technologies and solutions improve patient outcomes
and reduce cost of care. In the first half of the year we
introduced six important products, including Radius™ PPG, our Halo
ION™, and a neonatal version of our O3® Cerebral Oximetry monitor,
all of which should help fuel our momentum. With these new products
added to our existing portfolio and ever increasing global
footprint, we are delighted to be in a position to raise our
revenue and earnings guidance for 2019.”
2019 Financial Guidance
The Company provided the following updated estimates for its
full year 2019 guidance:
2019 Updated
Guidance(1)
Prior 2019 Guidance(1)
(in millions, except percentages and
earnings per share)
GAAP
Non-GAAP
GAAP
Non-GAAP
Total revenue
$
926.3
$
925.0
$
919.1
$
918.0
Product revenue
$
925.0
$
925.0
$
918.0
$
918.0
Percentage growth - as reported
11.5
%
11.5
%
10.6
%
10.6
%
Percentage growth - constant currency
N/A
12.2
%
N/A
11.4
%
Royalty and other revenue
$
1.3
$
—
$
1.1
$
—
Gross margin
66.8
%
66.8
%
66.8
%
66.8
%
Operating margin
23.9
%
24.0
%
23.9
%
24.0
%
Diluted earnings per share
$
3.30
$
3.15
$
3.25
$
3.12
EBITDA
26.4
%
30.5
%
26.4
%
30.5
%
Estimated tax rate
19.5
%
23.4
%
19.9
%
23.2
%
______________
(1) Updated guidance provided July 31, 2019. Prior guidance
provided May 6, 2019.
- Total revenue, including royalty and other revenue, increasing
to $926.3 million;
- Product revenue increasing 11.5% to $925.0 million, or 12.2% on
a constant currency basis;
- GAAP diluted earnings per share increasing to $3.30;
- Non-GAAP diluted earnings per share increasing 18.9% to $3.15;
and
- Included in our full year revenue guidance is approximately
$6.0 million of year-over-year currency headwinds.
Impact of Adoption of New Lease Accounting Standard
Effective December 30, 2018, we adopted Accounting Standards
Codification (ASC) Topic 842, Leases (ASC 842). Our adoption of ASC
842 generally resulted in (a) the recognition of lessee
right-of-use (ROU) assets for the right to use assets subject to
operating leases; (b) the recognition of lessee lease liabilities
for our obligation to make payments under operating leases; and (c)
the acceleration of when we recognize certain revenue and costs as
a lessor of equipment provided to end-user hospitals at no up-front
charge under deferred equipment agreements with fixed multi-year
sensor purchase commitments. For additional information with
respect to the impact of the adoption of this new accounting
standard, please reference Note 2 to our condensed consolidated
financial statements that will be included in Part I, Item 1 of our
Quarterly Report on Form 10-Q for the quarter ended June 29, 2019,
once filed with the Securities and Exchange Commission (SEC) and
Exhibit 99.3 that was included in our Current Report on Form 8-K
that was filed with the SEC today.
Supplementary Non-GAAP Financial Information
For additional non-GAAP financial details, please visit the
Investor Relations section of the Company’s website at www.masimo.com to access Supplementary Financial
Information.
Non-GAAP Financial Measures
The non-GAAP financial measures contained herein are a
supplement to the corresponding financial measures prepared in
accordance with U.S. GAAP. The non-GAAP financial measures
presented exclude the items described below. Management believes
that adjustments for these items assist investors in making
comparisons of period-to-period operating results. Furthermore,
management also believes that these items are not indicative of the
Company’s on-going core operating performance. These non-GAAP
financial measures have certain limitations in that they do not
reflect all of the costs associated with the operations of the
Company’s business as determined in accordance with GAAP.
Therefore, investors should consider non-GAAP financial measures
in addition to, and not as a substitute for, or as superior to,
measures of financial performance prepared in accordance with GAAP.
The non-GAAP financial measures presented by the Company may be
different from the non-GAAP financial measures used by other
companies.
The Company has presented the following non-GAAP measures to
assist investors in understanding the Company’s core net operating
results on an on-going basis: (i) constant currency product revenue
growth %, (ii) non-GAAP net income, (iii) non-GAAP diluted earnings
per share, (iv) non-GAAP gross profit/margin, (v) non-GAAP
operating income/margin, (vi) adjusted EBITDA. These non-GAAP
financial measures may also assist investors in making comparisons
of the Company’s core operating results with those of other
companies. Management believes constant currency product revenue
growth, non-GAAP gross profit/margin, non-GAAP operating
income/margin, non-GAAP net income, non-GAAP diluted earnings per
share and adjusted EBITDA are important measures in the evaluation
of the Company’s performance and uses these measures to better
understand and evaluate our business.
The non-GAAP financial measures reflect adjustments for the
following items, as well as the related income tax effects
thereof:
Constant currency adjustments.
Some of our sales agreements with foreign customers provide for
payment in currencies other than the U.S. Dollar. These foreign
currency revenues, when converted into U.S. Dollars, can vary
significantly from period to period depending on the average and
quarter-end exchange rates during a respective period. We believe
that comparing these foreign currency denominated revenues by
holding the exchange rates constant with the prior year period is
useful to management and investors in evaluating our product
revenue growth rates on a period-to-period basis. We anticipate
that fluctuations in foreign exchange rates and the related
constant currency adjustments for calculation of our product
revenue growth rate will continue to occur in future periods.
Royalty and other revenue, net of related
costs.
We derive royalty and other revenue, net of related costs, from
certain non-recurring contractual arrangements that we do not
expect to continue in the future. We believe the exclusion of
royalty and other revenue, net of related costs, associated with
these non-recurring revenue streams is useful to management and
investors in evaluating the performance of our ongoing operations
on a period-to-period basis.
Acquisition/strategic investment related
costs, including depreciation and amortization.
In the event the Company acquires, invests in or divests certain
business operations, there may be non-recurring gains, losses or
expenses that will be recognized related to the assets and/or
liabilities sold or acquired that are not representative of normal
on-going cash flows. Furthermore, there may be depreciation and
amortization related to the revaluation of assets and liabilities
(primarily intangible assets, property, plant and equipment
adjustments, inventory revaluation, lease liabilities, etc.) to
fair value through purchase accounting related to value created by
the seller prior to the acquisition/strategic investment that does
not reflect the normal on-going costs of operating our core
business. We believe that exclusion of these gains, losses or costs
in presenting non-GAAP financial measures provides management and
investors a more effective means of evaluating historical
performance and projected costs and the potential for realizing
cost efficiencies within our core business. Depreciation and
amortization related to the revaluation of acquisition related
assets and liabilities will generally recur in future periods.
Litigation damages, awards and
settlements.
In connection with litigation proceedings arising in the course
of our business, we have recorded expenses as a defendant in such
proceedings in the form of damages, as well as gains as a plaintiff
in such proceedings in the form of litigation awards and settlement
proceeds. We believe that exclusion of these gains and losses is
useful to management and investors in evaluating the performance of
our ongoing operations on a period-to-period basis. In this regard,
we note that these expenses and gains are generally unrelated to
our core business and/or infrequent in nature.
Realized and unrealized gains or losses
from foreign currency transactions.
We are exposed to foreign currency gains or losses on
outstanding foreign currency denominated receivables and payables
related to certain customer sales agreements, product costs and
other operating expenses. As the Company does not actively hedge
these currency exposures, changes in the underlying currency rates
relative to the U.S. Dollar may result in realized and unrealized
foreign currency gains and losses between the time these
receivables and payables arise and the time that they are settled
in cash. Since such realized and unrealized foreign currency gains
and losses are the result of macro-economic factors and can vary
significantly from one period to the next, we believe that
exclusion of such realized and unrealized gains and losses are
useful to management and investors in evaluating the performance of
our ongoing operations on a period-to-period basis. Realized and
unrealized foreign currency gains and losses are likely to recur in
future periods.
Excess tax benefits from stock-based
compensation.
Current authoritative accounting guidance requires that excess
tax benefits or costs recognized on stock-based compensation
expense be reflected in our provision for income taxes rather than
paid-in capital. Since we cannot control or predict when stock
option awards will be exercised or the price at which such awards
will be exercised, the impact of such guidance can create
significant volatility in our effective tax rate from one period to
the next. We believe that exclusion of these excess tax benefits or
costs is useful to management and investors in evaluating the
performance of our ongoing operations on a period-to-period basis.
These excess tax benefits or costs will generally recur in future
periods as long as we continue to issue equity awards to our
employees.
Tax impacts that may not be representative
of the ongoing results of our core operations.
From time-to-time, we may experience significant non-recurring
tax events, such as changes in tax laws and regulations or the
derecognition of uncertain tax positions related to non-recurring
transactions due to the expiration of the statutes of limitations.
We believe that exclusion of such tax charges or benefits is useful
to management and investors in evaluating the performance of our
ongoing operations on a period-to-period basis. In this regard, we
note that these tax items are unrelated to our core business and
generally unique and non-recurring in nature.
Adjusted EBITDA.
The Company defines adjusted EBITDA as earnings before
non-operating income/expense, taxes, depreciation and amortization,
as adjusted for the applicable non-GAAP adjustments described above
and further excluding non-cash stock based compensation expense. We
believe these adjustments to EBITDA provide investors and
management with a more consistent measurement of business
performance and aid in comparability from period to period.
Second Quarter 2019 Actuals versus
Second Quarter 2018 Actuals
RECONCILIATION OF GAAP TO NON-GAAP CONSTANT CURRENCY
PRODUCT REVENUE:
Three Months Ended
(in thousands, except
percentages)
June 29, 2019
June 30, 2018
GAAP product revenue
$
229,510
$
202,004
Non-GAAP constant currency
adjustments:
Constant currency F/X adjustments
2,351
N/A
Total non-GAAP constant currency
adjustments
2,351
N/A
Non-GAAP constant currency product
revenue
$
231,861
$
202,004
Product revenue growth %:
GAAP
13.6
%
Non-GAAP constant currency
14.8
%
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET
INCOME PER DILUTED SHARE(1):
Three Months Ended
June 29, 2019
June 30, 2018
(in thousands, except per share
amounts)
$
Per Diluted Share
$
Per Diluted Share
GAAP net income
$
44,888
$
0.79
$
43,853
$
0.79
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
(111
)
—
(9,415
)
(0.17
)
Acquisition/strategic investment related
costs
1,136
0.02
361
0.01
Non-operating other (income) expense
(7
)
—
566
0.01
Tax impact of pre-tax non-GAAP adjustments
above
(179
)
—
2,344
0.04
Excess tax benefits from stock-based
compensation
(2,608
)
(0.05
)
(3,947
)
(0.07
)
Total non-GAAP adjustments
(1,768
)
(0.03
)
(10,091
)
(0.18
)
Non-GAAP net income
$
43,120
$
0.76
$
33,763
$
0.61
Weighted average shares outstanding -
diluted
57,066
55,742
__________________
(1) May not foot due to rounding.
RECONCILIATION OF GAAP TO NON-GAAP OPERATING
MARGIN(1):
Three Months Ended
June 29, 2019
June 30, 2018
(in thousands, except
percentages)
$
$
GAAP operating income/margin
$
52,004
$
51,612
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
(111
)
(9,415
)
Acquisition/strategic investment related
costs
1,136
361
Total non-GAAP adjustments
1,025
(9,054
)
Non-GAAP operating income/margin
$
53,030
$
42,559
GAAP operating income/margin %
22.6
%
24.4
%
Non-GAAP operating income/margin %
23.1
%
21.1
%
__________________
(1) May not foot due to rounding.
Full Year 2019 Guidance versus Full
Year 2018 Actuals
RECONCILIATION OF GAAP PRODUCT REVENUE GROWTH %
TO
CONSTANT
CURRENCY PRODUCT REVENUE GROWTH %:
(in thousands, except
percentages)
Full Year 2019 Updated
Guidance(1)
Full Year 2018 Actuals
GAAP product revenue
$
925,000
$
829,874
Non-GAAP constant currency
adjustments:
Constant currency F/X adjustments
6,000
N/A
Total non-GAAP constant currency
adjustments
6,000
N/A
Non-GAAP constant currency product
revenue
$
931,000
$
829,874
Product revenue growth %:
GAAP
11.5
%
Non-GAAP constant currency
12.2
%
__________________
(1) Updated guidance provided July 31, 2019. Prior guidance
provided May 6, 2019.
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET
INCOME PER DILUTED SHARE(1):
Full Year 2019 Updated
Guidance(2)
Full Year 2018 Actuals
(in thousands, except per share
amounts)
$
Per Diluted Share
$
Per Diluted Share
GAAP net income
$
188,804
$
3.30
$
193,543
$
3.45
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
(1,159
)
(0.02
)
(27,704
)
(0.49
)
Acquisition/strategic investment related
costs
2,209
0.04
1,442
0.03
Litigation damages, awards and
settlements
—
—
425
0.01
Non-operating other (income) expense
(541
)
(0.01
)
2,027
0.04
Tax impact of pre-tax non-GAAP adjustments
above
63
—
5,532
0.10
Excess tax benefits from stock-based
compensation
(9,290
)
(0.16
)
(22,036
)
(0.39
)
Expiration of certain statutes of
limitations related to unique and non-recurring tax positions
—
—
(4,169
)
(0.07
)
2017 U.S. Tax Reform
—
—
(675
)
(0.01
)
Total non-GAAP adjustments
(8,718
)
(0.15
)
(45,157
)
(0.81
)
Non-GAAP product net income
$
180,087
$
3.15
$
148,385
$
2.65
Weighted average shares outstanding -
diluted
57,219
56,039
__________________
(1) May not foot due to rounding.
(2) Updated guidance provided July 31, 2019. Prior guidance
provided May 6, 2019.
RECONCILIATION OF GAAP TO NON-GAAP GROSS PROFIT AND
OPERATING MARGIN(1):
Full Year 2019 Updated
Guidance(2)
Full Year 2018 Actuals
(in thousands, except
percentages)
$
$
GAAP gross margin
$
618,601
$
574,892
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
(1,159
)
(27,704
)
Acquisition/strategic investment related
costs
458
458
Total non-GAAP adjustments
(701
)
(27,246
)
Non-GAAP gross margin
$
617,900
$
547,645
GAAP gross margin %
66.8
%
67.0
%
Non-GAAP gross margin %
66.8
%
66.0
%
GAAP operating income/margin
$
220,950
$
208,044
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
(1,159
)
(27,704
)
Acquisition/strategic investment related
costs
2,209
1,442
Litigation damages, awards and
settlements
—
425
Total non-GAAP adjustments
1,050
(25,837
)
Non-GAAP operating income/margin
$
222,000
$
182,206
GAAP operating income/margin %
23.9
%
24.2
%
Non-GAAP operating income/margin %
24.0
%
22.0
%
__________________
(1) May not foot due to rounding.
(2) Updated guidance provided July 31, 2019. Prior guidance
provided May 6, 2019.
RECONCILIATION OF EBITDA TO ADJUSTED
EBITDA(1):
Full Year 2019 Updated
Guidance(2)
Full Year 2018 Actuals
(in thousands, except
percentages)
$
% of Revenue
$
% of Revenue
GAAP net income
$
188,804
20.4
%
$
193,543
22.5
%
Other (income)/expense(3)
(13,641
)
(1.5
)
(5,732
)
(0.7
)
Provision for income taxes
45,787
4.9
20,233
2.4
Depreciation and amortization
23,363
2.5
21,127
2.5
EBITDA
244,313
26.4
229,171
26.7
Add: Non-cash stock-based compensation
expense
38,079
4.1
27,417
3.2
Add: Litigation damages, awards and
settlements
—
—
425
—
Adjusted EBITDA
$
282,392
30.5
%
$
257,013
29.9
%
__________________
(1) May not foot due to rounding.
(2) Updated guidance provided July 31, 2019. Prior guidance
provided May 6, 2019.
(3) Other (income)/expense consists primarily of interest
(income)/expense and net foreign currency (gains)/losses.
Conference Call
Masimo will hold a conference call today at 1:30 p.m. PT (4:30
p.m. ET) to discuss the results. A live webcast of the call will be
available online from the investor relations page of the Company’s
website at www.masimo.com. The dial-in numbers are (888) 520-7182
for domestic callers and +1 (706) 758-3929 for international
callers. The reservation code for both dial-in numbers is 3195569.
After the live webcast, the call will be available on Masimo’s
website through August 7, 2019. In addition, a telephonic replay of
the call will be available through August 30, 2019. The replay
dial-in numbers are (855) 859-2056 for domestic callers and +1
(404) 537-3406 for international callers. Please use reservation
code 3195569.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care. In 1995, the Company
debuted Masimo SET® Measure-through Motion and Low Perfusion® pulse
oximetry, which has been shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms. Masimo
SET® is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world.
In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®) and more recently, Oxygen Reserve Index
(ORi™), in addition to SpO2, pulse rate and perfusion index (PI).
In 2014, Masimo introduced Root™, an intuitive patient monitoring
and connectivity platform with the Masimo Open Connect® (MOC-9®)
interface. Masimo is also taking an active leadership role in
mobile health applications (mHealth) with products such as the
Radius-7® wearable patient monitor and the MightySat™ fingertip
pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
Forward-Looking Statements
All statements other than statements of historical facts
included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may
occur in the future are forward-looking statements including, in
particular, the statements about our expectations for full fiscal
year GAAP and non-GAAP 2019 total revenue, product revenue, royalty
and other revenues, gross margin, operating margin, diluted
earnings per share, EBITDA, estimated tax rate and our long-term
outlook; demand for our products; anticipated revenue and earnings
growth; our financial condition, results of operations and business
generally; expectations regarding our ability to design and deliver
innovative new noninvasive technologies and reduce the cost of
care; and demand for our technologies. These forward-looking
statements are based on management’s current expectations and
beliefs and are subject to uncertainties and factors, all of which
are difficult to predict and many of which are beyond our control
and could cause actual results to differ materially and adversely
from those described in the forward-looking statements. These risks
include, but are not limited to, those related to: our dependence
on Masimo SET® and Masimo rainbow SET™ products and technologies
for substantially all of our revenue; any failure in protecting our
intellectual property exposure to competitors’ assertions of
intellectual property claims; the highly competitive nature of the
markets in which we sell our products and technologies; any failure
to continue developing innovative products and technologies; the
lack of acceptance of any of our current or future products and
technologies; obtaining regulatory approval of our current and
future products and technologies; the risk that the implementation
of our international realignment will not continue to produce
anticipated operational and financial benefits, including a
continued lower effective tax rate; the loss of our customers; the
failure to retain and recruit senior management; product liability
claims exposure; a failure to obtain expected returns from the
amount of intangible assets we have recorded; the maintenance of
our brand; the amount and type of equity awards that we may grant
to employees and service providers in the future; our ongoing
litigation and related matters; and other factors discussed in the
“Risk Factors” section of our most recent periodic reports filed
with the Securities and Exchange Commission (“SEC”), including our
most recent Form 10-K and Form 10-Q, all of which you may obtain
for free on the SEC’s website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove
correct. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient
Outcome and Reducing Cost of Care... by Taking Noninvasive
Monitoring to New Sites and Applications, rainbow, SpHb, SpOC,
SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of
Masimo Corporation.
MASIMO CORPORATION
CONDENSED CONSOLIDATED BALANCE
SHEETS
(unaudited, in
thousands)
June 29, 2019
December 29, 2018
ASSETS
Current assets
Cash and cash equivalents
$
408,784
$
552,490
Short-term investments
180,000
—
Accounts receivable, net of allowance for
doubtful accounts
120,580
109,629
Inventories
98,785
94,732
Other current assets
55,894
29,227
Total current assets
864,043
786,078
Lease receivable, noncurrent
44,284
—
Deferred costs and other contract
assets
13,998
126,105
Property and equipment, net
202,810
165,972
Intangible assets, net
27,633
27,924
Goodwill
22,384
23,297
Deferred tax assets
30,475
21,210
Other non-current assets
24,219
4,232
Total assets
$
1,229,846
$
1,154,818
LIABILITIES AND STOCKHOLDERS’
EQUITY
Current liabilities
Accounts payable
$
36,472
$
40,388
Accrued compensation
42,439
49,486
Deferred revenue and other
contract-related liabilities, current
25,874
33,106
Other current liabilities
31,289
24,627
Total current liabilities
136,074
147,607
Other non-current liabilities
53,898
38,146
Total liabilities
189,972
185,753
Commitments and contingencies
Stockholders’ equity
Common stock
53
53
Treasury stock
(516,880
)
(489,026
)
Additional paid-in capital
564,697
533,164
Accumulated other comprehensive loss
(6,484
)
(6,199
)
Retained earnings
998,488
931,073
Total stockholders’ equity
1,039,874
969,065
Total liabilities and stockholders’
equity
$
1,229,846
$
1,154,818
MASIMO CORPORATION
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(unaudited, in thousands,
except per share amounts)
Three Months Ended
Six Months Ended
June 29, 2019
June 30, 2018
June 29, 2019
June 30, 2018
Revenue:
Product
$
229,510
$
202,004
$
460,058
$
406,393
Royalty and other revenue
142
9,617
1,258
18,181
Total revenue
229,652
211,621
461,316
424,574
Cost of goods sold
75,313
69,474
155,335
138,766
Gross profit
154,339
142,147
305,981
285,808
Operating expenses:
Selling, general and administrative
78,160
70,450
152,364
140,667
Research and development
24,175
20,085
45,590
39,644
Total operating expenses
102,335
90,535
197,954
180,311
Operating income
52,004
51,612
108,027
105,497
Non-operating income
3,529
1,405
7,415
3,052
Income before provision for income
taxes
55,533
53,017
115,442
108,549
Provision for income taxes
10,645
9,164
21,232
19,066
Net income
$
44,888
$
43,853
$
94,210
$
89,483
Net income per share:
Basic
$
0.84
$
0.84
$
1.77
$
1.72
Diluted
$
0.79
$
0.79
$
1.65
$
1.60
Weighted-average shares used in per share
calculations:
Basic
53,356
51,999
53,283
52,047
Diluted
57,066
55,742
56,940
55,842
The following table presents details of the stock-based
compensation expense that is included in each functional line item
in the condensed consolidated statements of operations (in
thousands):
Three Months Ended
Six Months Ended
June 29, 2019
June 30, 2018
June 29, 2019
June 30, 2018
Cost of goods sold
$
132
$
73
$
229
$
151
Selling, general and administrative
8,888
5,293
14,613
9,329
Research and development
2,453
1,354
3,948
2,572
Total
$
11,473
$
6,720
$
18,790
$
12,052
MASIMO CORPORATION
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
(unaudited, in
thousands)
Six Months Ended
June 29, 2019
June 30, 2018
Cash flows from operating
activities:
Net income
$
94,210
$
89,483
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization
11,641
10,794
Stock-based compensation
18,790
12,049
Loss on disposal of property, equipment
and intangibles
93
632
Provision from doubtful accounts
622
(356
)
Provision (benefit) from deferred income
taxes
21
(274
)
Changes in operating assets and
liabilities:
(Increase) decrease in accounts
receivable
(11,705
)
20,209
(Increase) decrease in inventories
(4,159
)
1,075
Increase in other current assets
(7,147
)
(1,694
)
Increase in lease receivable, net
(6,238
)
—
Decrease (increase) in deferred costs and
other contract assets
8,723
(7,809
)
(Increase) decrease in other non-current
assets
(177
)
430
(Decrease) increase in accounts
payable
(2,841
)
1,820
Decrease in accrued compensation
(6,997
)
(2,771
)
(Decrease) increase in accrued
liabilities
(2,966
)
1,776
Increase (decrease) in income tax
payable
2,109
(895
)
Increase in deferred revenue and other
contract-related liabilities
5,566
3,397
Increase in other non-current
liabilities
1,234
33
Net cash provided by operating
activities
100,779
127,899
Cash flows from investing
activities:
Purchases of short-term investments
(180,000
)
—
Purchases of property and equipment,
net
(47,323
)
(9,430
)
Increase in intangible assets
(2,019
)
(3,643
)
Net cash used in investing
activities
(229,342
)
(13,073
)
Cash flows from financing
activities:
Proceeds from issuance of common stock
12,870
19,778
Payroll tax withholdings on behalf of
employees for vested equity awards
(123
)
(168
)
Repurchases of common stock
(27,854
)
(18,478
)
Net cash (used in) provided by
financing activities
(15,107
)
1,132
Effect of foreign currency exchange rates
on cash
(32
)
(1,647
)
Net (decrease) increase in cash, cash
equivalents, and restricted cash
(143,702
)
114,311
Cash, cash equivalents and restricted cash
at beginning of period
552,641
315,483
Cash, cash equivalents and restricted cash
at end of period
$
408,939
$
429,794
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190731005968/en/
Investor Contact: Eli Kammerman (949) 297-7077
ekammerman@masimo.com
Media Contact: Irene Paigah (858) 859-7001
irenep@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024